Efficacy and Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin in Atrial Fibrillation in Different Age Subgroups  by Clemens, Andreas et al.
aClinic
GmbH&C
Hemostasi
Germany; c
ofMedicin
eHealth Ec
maceutical
2014; revis
*This
creativecom
See pa
*Corre
E-mail
0002-9149
Inc. All rig
http://dx.doEfﬁcacy and Cost-Effectiveness of Dabigatran Etexilate
Versus Warfarin in Atrial Fibrillation in DifferentAge Subgroups*
Andreas Clemens, MDa,b, Siyang Peng, MSc, Sarah Brand, BAc, Martina Brueckmann, MDa,d,
Anuraag Kansal, PhDc, Jonathan Lim, MSe, Herbert Noack, PhDa, Stephen Sander, PharmDe,
and Sonja Sorensen, MPHc,*
This study aims to estimate the cost-effectiveness of dabigatran 150 mg twice daily versusal Deve
oKG, I
s, Joha
Modeli
eMann
onomic
s, Inc.,
ed man
is an op
mons.
ge 854
spondin
addres
/14/$ -
hts rese
i.org/1warfarin for stroke and systemic embolism risk reduction in patients with nonvalvular
atrial ﬁbrillation initiating treatment before age 75 (<75), at or after age 75 (‡75), and the
overall population (All) from a US Medicare payer perspective. Clinical event rates by age
cohort with dabigatran or warfarin for safety-on-treatment and intent-to-treat populations
were estimated from Randomized Evaluation of Long-Term Anticoagulation Therapy
(RE-LY). An economic model was adapted using these data to evaluate the impact of
starting age on clinical and economic outcomes. Costs were obtained from Medicare pay-
ment schedules and utilities from publications. Model outputs included event rates, costs,
quality-adjusted life-years, and incremental cost-effectiveness ratios. The RE-LY analysis
shows that the <75 cohort has lower rates of all events than the ‡75 cohort; versus warfarin,
dabigatran performed better in main efﬁcacy and safety in all age cohorts with the
exception of extracranial hemorrhage in the ‡75 cohort. The clinical event costs avoided per
patient for dabigatran were $1,100, $135, and $713 for cohorts <75, ‡75, and All, respec-
tively. Extrapolating over a lifetime horizon, the model found that dabigatran resulted in
lower rates of stroke and intracranial hemorrhage and higher rates for extracranial hem-
orrhage versus warfarin for all age cohorts. Lifetime quality-adjusted life-years and costs
were higher for dabigatran than warfarin, resulting in incremental cost-effectiveness ratios
of $52,773, $65,946, and $56,131 for cohorts <75, ‡75, and All, respectively. In conclusion,
dabigatran was cost-effective versus warfarin in US patients with atrial ﬁbrillation
regardless of age of treatment initiation.  2014 The Authors. Published by Elsevier Inc.
All rights reserved. (Am J Cardiol 2014;114:849e855)Atrial ﬁbrillation (AF) is a common arrhythmia and the
leading cause of stroke, which is associated with a high
humanistic and economic burden.1 The Randomized Eval-
uation of Long-Term Anticoagulation Therapy (RE-LY)
trial demonstrated the safety and efﬁcacy of dabigatran
versus warfarin for the prevention of stroke and systemic
embolism, and in additional analyses, the efﬁcacy and safety
by age cohorts in patients with AF at moderate to high risk
of stroke.2,3 The effects of dabigatran compared with
warfarin on stroke or systemic embolism were consistent
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0.1016/j.amjcard.2014.06.015interaction was seen in major bleeding outcomes. In the
dabigatran 150 mg twice daily dose arm, the dose approved
by the FDA, patients <75 years had lower rates of intra-
cranial hemorrhage (ICH) and extracranial hemorrhage
(ECH) than those treated with warfarin, whereas patients
75 years had a lower risk of ICH but higher rates of ECH
than warfarin-treated patients.3,4 In addition, the overall risk
of stroke increases with age, as indicated by the CHADS2
scoring increasing by a point at age 75. Given the different
safety results by age group and the increasing risk of stroke
with age, there is a need to understand the cost-effectiveness
for each age group. The objective of this study is to inves-
tigate the cost-effectiveness of dabigatran etexilate 150 mg
twice daily versus warfarin in patients with AF in whom
anticoagulation is appropriate, in cohorts initiating treatment
before age 75 (<75), those initiating at or after age 75
(75), and all RE-LY trial patients (All) from a US payer
perspective. The analysis uses efﬁcacy and safety data of the
RE-LY trial by age cohorts speciﬁcally generated from in-
dividual patient data for this analysis.Methods
A previously published Markov model was adapted to
simulate anticoagulation treatment in individual age cohortswww.ajconline.org
Table 1
Model costs
Drug Costs Per Day Source*
Dabigatran 150 mg twice
daily
$8.84 Red Book20
Warfarin $0.16 Red Book20
Aspirin $0.01 Red Book20
Treatment Monitoring Cost Annual Source
Warfarin $285.10 Assume 14
international
normalized ratio
tests Shah et al19
Physicians fee and
Coding Guide 2012
(CPT 99211)21
Event Costs Per Acute
Event
Source
Ischemic stroke, fatal and
non-fatal
$22,653.16 Mercaldi et al 201211
Systemic embolism, fatal and
non-fatal
$7,291.83 Mercaldi et al 201110
Transient ischemic attack $3,905.03 Mercaldi et al 201110
Intracranial hemorrhage and
hemorrhagic stroke
$34,572.50 Mercaldi et al 201211
Extracranial hemorrhage
(non-brain), fatal and
non-fatal
$16,769.55 Mercaldi et al 201211
Minor bleed $211.05 Physicians fee and
Coding Guide 2012
(CPT 99215)21
Acute myocardial infarction,
fatal
$5,447.99 DRG 283, 284, 285
Acute myocardial infarction,
non-fatal
$6,560.89 DRG 280, 281, 282
Follow-up Costs Per Quarter Source
Independent with stroke
history
$203.67 Mercaldi et al 2012;
Luengo-Fernandez
et al 201211,12Moderate disability $1,764.56
Dependent disability $3,746.33
* Drug costs were obtained January 2014. All the other costs were
inﬂated to 2013 value.
850 The American Journal of Cardiology (www.ajconline.org)and the resulting clinical events in the United States.5e7 The
model followed patients with nonvalvular AF at risk of
relevant clinical events through the natural course of the
disease until the end of their lives. Using a US Medicare
payer perspective, a lifetime horizon was considered in the
base case.
The clinical events included were primary and recurrent
ischemic stroke, transient ischemic attack, systemic embo-
lism, acute myocardial infarction, ICH (including hemor-
rhagic stroke), ECH, and death. Patients could experience
no clinical event, 1 of the events, and/or death during any
3-month model cycle. The key consequences of the clinical
events were a change in treatment status (switching treat-
ment to aspirin or permanent discontinuation of treatment), a
change in functional disability after a stroke or ICH (deﬁned
by modiﬁed Rankin Score [strokes] or Glasgow Outcomes
Scale [ICH]), and/or a reduction in quality of life and death.Patients could also switch treatment for reasons not related
to a clinical event. Patients were also subject to mortality
from other causes at every cycle using age-, gender-, and
event-adjusted all-cause mortality data.
Three patient cohorts were deﬁned: those initiating
anticoagulation treatment <75 years, 75 years, and all
patients (All). Gender distribution and acute myocardial
infarction history were assigned at baseline. Each cohort
included subcohorts for each year of age at baseline with
speciﬁc CHADS2 and previous stroke distribution for that
baseline age obtained from a RE-LY analysis by starting
age.
Also obtained from the age analysis were the baseline
risks of each event while on warfarin and the relative risks
of dabigatran versus warfarin. In addition to the bleeding
events in the intent-to-treat population reported by Eikel-
boom et al,3 the new analysis reported all clinical events for
patients in each cohort for both the safety-on-treatment and
the intent-to-treat populations.
The safety-on-treatment population data (based only on
patients who received at least 1 dose of a study drug and
were followed for events from ﬁrst to last dose plus 6 days,
regardless of adherence to the protocol or temporary dis-
continuations2) were used for the “on-treatment” health
states in the model, whereas the treatment efﬁcacy of aspirin
and no treatment were applied for patients who switched or
discontinued treatment. The use of the safety-on-treatment
population for the clinical outcomes avoided double
counting of the effects of treatment discontinuation.
The baseline risks of clinical events were based on rates
in the warfarin arm for patients aged <75. Relative risks of
the age (75 vs <75) and treatment (dabigatran vs warfarin)
were calculated using age-stratiﬁed data from RE-LY.
Relative risks of aspirin and no treatment versus warfarin
were obtained from a network meta-analysis.8 Postevent
disability was based on analysis of the RE-LY trial.9 For
patients receiving warfarin, 22.1% of ischemic stroke events
were fatal; and 4.3%, 19.7%, and 53.9% were completely
dependent, moderately dependent, and independent func-
tioning after ischemic stroke events, respectively. This dis-
tribution was 25.1%, 1.6%, 15.6%, and 57.7%, respectively,
in the dabigatran arm. After ICH events, 51.6% of the events
were fatal, 31.8% of the patients were completely depen-
dent, 8.8% were moderately dependent, and 7.8% were in-
dependent functioning regardless of current anticoagulation
treatment. The proportions of ECH that are gastrointestinal
bleeding were obtained from RE-LY and estimated to be
48.7% and 35.7% in the dabigatran and warfarin arms,
respectively.
Event and disability costs were calculated using Medi-
care reimbursement data (Table 1). The acute event costs
and long-term follow-up costs were obtained from a data-
base analysis on the long-term costs of stroke and major
bleeding events in patients with nonvalvular AF.10,11 The
study analyzed cost data of nondisabled Medicare patients.
In contrast to commercial claims data sources, Medicare has
a large number of patients older than 65 years, which ﬁts the
model population well. The cost components included in the
analysis are inpatient hospital, outpatient hospital, skilled
nursing facility, hospice, home health agency, and durable
medical equipment. The study captured costs up to 3 years
Table 2
Annual probability and relative risk of clinical events, safety-on-treatment, and intent-to-treat populations
Variable Warfarin Dabigatran 150 mg Twice Daily
Annual Rate Per
100 Patient-years,
Age <75
Annual Rate Per
100 Patient-years,
Age 75
Relative Risk,
Age <75 vs. Warfarin
Relative Risk,
Age 75 vs. Warfarin
Safety-on-treatment
Ischemic stroke, CHADS2 ¼ 0e1* 0.61 0.82 0.75 (0.37, 1.55) 0.95 (0.27, 3.28)
Ischemic stroke, CHADS2 ¼ 2* 0.79 1.06 0.64 (0.29, 1.40) 0.58 (0.27, 1.24)
Ischemic stroke, CHADS2 ¼ 3e4* 1.51 1.36 0.64 (0.33, 1.24) 0.80 (0.41, 1.55)
Ischemic stroke, CHADS2 ¼ 5e6* 2.28 3.47 0.93 (0.13, 6.63) 0.43 (0.13, 1.43)
Systemic embolism* 0.14 0.19 0.57 (0.19, 1.69) 0.40 (0.11, 1.51)
Stroke/systemic embolism 1.31 1.87 0.56 (0.39, 0.80) 0.56 (0.38, 0.82)
Transient ischemic attack* 0.71 1.10 0.80 (0.52, 1.23) 0.78 (0.50, 1.22)
Intracranial hemorrhage (including hemorrhagic stroke)* 0.60 1.03 0.34 (0.18, 0.63) 0.30 (0.16, 0.56)
Extracranial hemorrhage* 2.36 3.47 0.80 (0.63, 1.02) 1.50 (1.21, 1.86)
Acute myocardial infarction* 0.49 0.74 1.40 (0.89, 2.21) 1.20 (0.74, 1.95)
Minor bleeds* 16.76 19.15 0.80 (0.74, 0.88) 1.09 (0.99, 1.20)
Disabling or fatal stroke 0.76 1.03 0.48 (0.29, 0.78) 0.54 (0.33, 0.91)
Death from any cause 2.47 2.92 0.69 (0.54, 0.89) 1.01 (0.79, 1.31)
Intent-to-treat
Ischemic stroke, CHADS2 0e1 0.72 0.91 0.65 (0.34, 1.25) 0.74 (0.23, 2.43)
Ischemic stroke, CHADS2 2 0.77 1.29 0.77 (0.38, 1.57) 0.59 (0.31, 1.11)
Ischemic stroke, CHADS2 3e4 1.74 1.76 0.79 (0.45, 1.37) 0.87 (0.52, 1.46)
Ischemic stroke, CHADS2 5e6 2.05 3.82 0.98 (0.14, 6.96) 0.90 (0.38, 2.12)
Systemic embolism 0.16 0.21 0.72 (0.29, 1.78) 0.49 (0.17, 1.43)
Stroke/systemic embolism 1.42 2.15 0.63 (0.46, 0.86) 0.67 (0.49, 0.90)
Transient ischemic attack 0.70 1.04 0.83 (0.55, 1.25) 0.90 (0.60, 1.35)
Intracranial hemorrhage (including hemorrhagic stroke) 0.61 1.00 0.43 (0.25, 0.74) 0.39 (0.23, 0.67)
Extracranial hemorrhage 2.44 3.45 0.78 (0.62, 0.97) 1.39 (1.14, 1.71)
Acute myocardial infarction 0.54 0.79 1.34 (0.88, 2.03) 1.20 (0.77, 1.85)
Minor bleeds 15.70 17.39 0.81 (0.74, 0.88) 1.06 (0.97, 1.17)
Disabling or fatal stroke 0.80 1.32 0.59 (0.38, 0.90) 0.73 (0.50, 1.06)
Death from any cause 3.47 5.13 0.77 (0.63, 0.92) 0.99 (0.83, 1.19)
* Used in model.
Source: RE-LY age cohort analysis.
Figure 1. Baseline CHADS2 distribution within each age cohort. Source: RE-LY age cohort analysis.
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based on costs of the ﬁrst 3 months postevent. Long-term
follow-up costs were based on average costs from the
fourth month through 3 years postevent, prorated to ﬁt the
model cycles. Stratiﬁcation of the long-term follow-up costs
by disability level was not available from the study byMercaldi et al.11 To differentiate the cost consequences of
stroke and bleeding events resulting in different disability
levels, the unstratiﬁed follow-up costs were adjusted to
reﬂect the dependence of costs on disability level according
to a population-based study on long-term care cost of
patients with AF in the United Kingdom.12 All costs were
Table 3
Model results: events per 100 patient-years by age, lifetime analysis
Dabigatran
Age <75 Age 75 All Patients
All events (excluding minor bleed)* 9.31 9.86 9.47
Ischemic stroke (overall) 1.84 1.60 1.77
Ischemic stroke (disabling and
fatal)
0.88 0.74 0.84
Intracranial hemorrhage and
hemorrhagic stroke
0.41 0.41 0.41
Extracranial hemorrhage 4.55 5.45 4.80
Acute myocardial infarction 1.16 1.10 1.14
Systemic embolism and transient
ischemic attack
1.35 1.30 1.34
Minor bleed 20.31 21.04 20.51
Warfarin
Age <75 Age 75 All Patients
All events (excluding minor bleed)* 9.45 9.50 9.47
Ischemic stroke (overall) 2.13 1.96 2.09
Ischemic stroke (disabling and
fatal)
1.17 1.05 1.14
Intracranial hemorrhage and
hemorrhagic stroke
0.96 1.07 0.99
Extracranial hemorrhage 3.86 3.96 3.88
Acute myocardial infarction 0.93 0.93 0.93
Systemic embolism and transient
ischemic attack
1.57 1.59 1.57
Minor bleed 21.12 20.03 20.81
* All events (excluding minor bleed) include ischemic stroke, systemic
embolism, transient ischemic attack, intracranial hemorrhage & hemor-
rhagic stroke, extracranial hemorrhage and acute myocardial infarction.
Table 4
Model results: event and long-term follow-up costs per patient by age,
lifetime analysis
Dabigatran
Age <75 Age 75 All Patients
All Events* 13,242 9,560 11,771
Ischemic stroke (overall) 3,627 2,146 3,035
Ischemic stroke (disabling and
fatal)
3,257 1,948 2,813
Intracranial hemorrhage and
hemorrhagic stroke
1,289 846 1,112
Extracranial hemorrhage 6,723 5,532 6,247
Acute myocardial infarction 678 431 579
Systemic embolism and transient
ischemic attack
849 558 752
Minor bleed 76 47 46
Long-term follow-up 5,679 2,457 4,391
Warfarin
Age <75 Age 75 All Patients
All Events* 14,342 9,693 12,484
Ischemic stroke (overall) 4,129 2,581 3,510
Ischemic stroke (disabling and
fatal)
3,758 2,377 3,288
Intracranial hemorrhage and
hemorrhagic stroke
2,928 2,182 2,630
Extracranial hemorrhage 5,732 3,909 5,004
Acute myocardial infarction 532 357 462
Systemic embolism and transient
ischemic attack
938 620 828
Minor bleed 83 44 50
Long-term follow-up 8,029 3,621 6,267
* All events include IS, SE, TIA, ICH & HS, ECH, minor bleed and
AMI.
852 The American Journal of Cardiology (www.ajconline.org)adjusted to 2013 values using the medical component of the
consumer price index.8 Acute event costs not available from
the study by Mercaldi et al10,11 were based on the US
diagnosis-related group data.13 Health-related quality of life
was calculated for each health state using published utility
data.7,14,15
Model outcomes presented in this analysis include the
number of clinical events per 100 patient-years, total costs,
breakdown by cost type, and quality-adjusted life-years
(QALYs). Incremental cost-effectiveness ratios (ICERs)
were also computed as incremental cost in the dabigatran
arm versus the warfarin arm divided by incremental
QALYs. These analyses were conducted for each of the 3
age cohorts. All costs and outcomes were discounted by 3%
annually.16
The model was validated by comparing the results of the
model output over a 2-year time horizon for dabigatran and
warfarin with the intent-to-treat results of the RE-LY trial.
One-way sensitivity analyses were performed by varying
time horizon and discount rates, and clinical inputs such as
relative risks (upper and lower 95% conﬁdence interval
[CI]), event rates, treatment discontinuation, and event and
long-term follow-up costs. Because starting age determines
the length of a lifetime analysis, a limited time horizon of
10 years was examined to create a similar follow-up time for
the 3 cohorts. Relative risks were varied based on the 95%
CI. A scenario with event rates based on the intent-to-treatpopulation and excluding treatment discontinuation was
also explored. Scenario analyses were also conducted to
investigate the impact of aging and stroke events on
ischemic stroke risk.
A probabilistic sensitivity analysis characterized the
uncertainty surrounding the cost-effectiveness results. All
model parameters were simultaneously varied based on
statistical distribution and their 95% CI. Beta distributions
were assumed for baseline event probabilities and utility
estimates, log-normal distributions for relative risks, and
gamma distributions for event and health state costs.Results
The results of the RE-LY analysis by initiating age
cohort for the safety-on-treatment and intent-to-treat pop-
ulations are presented in Table 2. Rates of all events were
higher in the older cohort at treatment initiation versus the
younger cohort. In the intent-to-treat population, the annual
risks of ischemic stroke in the warfarin arm increased
steadily with the baseline CHADS2 score in both age co-
horts. Dabigatran treatment was associated with a lower risk
of stroke across all CHADS2 scores for both age cohorts.
However, because of small sample sizes, no trends in the
relative risks of dabigatran versus warfarin were seen in
terms of increasing CHADS2 risk. In the <75 age cohort,
Table 5
Model results: total and incremental costs and quality-adjusted life-years
over a lifetime analysis
Age <75 Age 75 All Patients
Total costs ($)
Dabigatran 46,444 28,645 39,331
Warfarin 25,485 15,178 21,366
Total QALYs
Dabigatran 9.69 5.62 8.07
Warfarin 9.30 5.42 7.75
Incremental results—dabigatran vs. warfarin
Costs ($) 20,960 13,467 17.965
QALYs 0.40 0.20 0.32
ICER ($/QALY) 52,773 65,946 56,131
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treated patients, except a numerical increase in acute
myocardial infarction. In the older cohort, dabigatran had
lower risk of all events except acute myocardial infarction,
minor bleeds, and ECH. The distributions of baseline
CHADS2 scores by age are presented in Figure 1. In the
group of patients between 65 and 75 years, there was a
greater proportion of patients in lower CHADS2 categories
than in older patients.
The validation analysis showed that the event rates pre-
dicted in the model largely matched the event rates in the
intent-to-treat population from the RE-LY trial, with all
model outcomes within 5% of the trial intent-to-treat pop-
ulation except ECH (overestimated for dabigatran by 9%)
and transient ischemic attack (overestimated in both arms by
10%). This validation demonstrates that the model repli-
cated the clinical trial with on-treatment clinical inputs
based on safety-on-treatment data and simulated effects of
treatment switching and discontinuation.
The model calculated overall and speciﬁc clinical events
per 100 patient-years (Table 3). In all age subgroups, the
model found that in comparison with warfarin-treated
patients, dabigatran-treated patients experienced fewer
instances of ischemic stroke and ICH and more instances of
ECH and acute myocardial infarction over the lifetime ho-
rizons. The differences in the number of events experienced
per 100 patient-years by dabigatran versus warfarin-treated
patients were the greatest in the age 75 cohort, with the
exception of acute myocardial infarction for which the age
<75 cohort showed the greatest difference.
The use of dabigatran resulted in lower total event costs
and lower long-term follow-up costs per patient than
warfarin in all age subgroups (Table 4). Compared with
warfarin, dabigatran reduced the per-patient costs of
ischemic stroke and ICH and the follow-up costs of the
resulting long-term disability and increased the per-patient
costs of ECH and acute myocardial infarction over the
lifetime horizon, consistent with the clinical efﬁcacy for
each event. The total costs avoided per patient because of
event for dabigatran were $1,100, $135, and $713, and the
total costs avoided per patient in the long-term follow-up to
disability outcomes resulting from clinical events were
$3,450, $1,297, and $2,589 for patient cohorts <75, 75,
and All, respectively. The differences in total medical costs
were the greatest in the age <75 cohort.Table 5 presents mean total costs, total QALYs, and in-
cremental cost per QALY gained (i.e., ICER) per patient
comparing dabigatran with warfarin. Dabigatran-treated
patients accrued more QALYs than warfarin-treated pa-
tients in all the cohorts. Dabigatran-treated patients also had
a higher cost versus warfarin-treated patients in all the
cohorts. The lowest (most favorable to dabigatran) ICER
was seen in the cohort initiating anticoagulation treatment
before age 75.
Sensitivity analyses showed that dabigatran remained a
<$100,000/QALY willingness-to-pay threshold for all
variations in model input parameters, except for relative risk
of ischemic stroke and time horizon. The most signiﬁcant
driver of cost-effectiveness was the relative risk of ischemic
stroke (ICER range $42,062 to $213,652 for all patients
cohort). Other important drivers were the relative risks
of ICH, ECH, and acute myocardial infarction in all age
cohorts (ICER range $48,175 to $83,582). An analysis time
horizon shorter than lifetime also affected results, especially
for the age <75 cohort (time horizon of 10 years ICER of
$115,256). Similarly, the variations of both health and cost
discount rates showed greater impact in the age <75 cohort
than in the age 75 cohort, as this younger cohort remained
in the model gaining QALYs and costs over a longer time.
Varying the cost of event and long-term follow-up by 20%
results in <5% change in the ICER. The probabilistic
sensitivity analysis also found relatively stable predicted
ICERs of dabigatran. In the probabilistic sensitivity anal-
ysis, dabigatran was cost effective relative to warfarin in
95%, 79%, and 95% of simulations at a willingness-to-pay
threshold of $100,000, for age <75, 75, and overall
cohorts, respectively.
The base-case and sensitivity analyses used safety-on-
treatment data from the RE-LY trial to inform the clinical
inputs with treatment discontinuation because of nonclinical
reason incorporated explicitly to reproduce the intent-to-
treat results. A scenario analysis was conducted using
intent-to-treat estimates to inform the clinical inputs and
assuming the treatment beneﬁt continued until treatment
switch because of clinical reason. This analysis yielded
ICER estimates approximately 14% greater than the base-
case estimates in all age cohorts. This greater ICER re-
ﬂects that in this scenario, clinical efﬁcacy is estimated
based on the average of those that remain on treatment and
those that have discontinued, but all patients, except those
discontinuing for clinical reasons, accrue the full drug costs.
Discussion
This study used age-adjusted estimates of clinical event
risks to evaluate the cost-effectiveness of 150 mg twice
daily dabigatran versus warfarin in different age cohorts in
the US Medicare payer setting. The base-case lifetime
analysis showed that the <75 cohort, on average, experi-
enced more ischemic strokes per 100 patient-years than the
75 cohort. As expected, the weighted average ischemic
stroke risk for warfarin was initially lower in the <75 cohort
(0.897 and 1.292 for the age <75 and age 75 cohorts,
respectively). As the entire younger cohort aged beyond 75
years, however, their CHADS2 scores increased by 1 point
for all patients, raising the weighted average ischemic stroke
854 The American Journal of Cardiology (www.ajconline.org)risk to 1.361. Thus, the <75 cohort spends a signiﬁcant
fraction of time at a higher risk than the baseline risk of the
older cohort. Additionally, the <75 cohort has more time to
experience a stroke (which raises CHADS2 score by 2 points
in the cohort resulting in a weighted average ischemic stroke
risk of 2.253 for the <75 cohort). Because of these increases
in risk over time, a cohort with a younger starting age
experienced more ischemic strokes per 100 patient-years
than a cohort with an older starting age with the same
CHADS2 score at baseline.
The effect of aging was also reﬂected in ECH results.
Although in the age <75 cohort, dabigatran-treated patients
have lower ECH risk than warfarin-treated patients (relative
risk 0.80), in the age 75 cohort, dabigatran-treated patients
have higher ECH risk (relative risk 1.50). Because of the
effect of aging, over a lifetime horizon, the dabigatran-
treated patients with starting age <75 and initial ECH risk
lower than warfarin-treated patients experienced more ECH
per 100 patient-years than warfarin-treated patients.
The key model drivers for determining cost-effectiveness
were ischemic stroke risk and time horizon. These 2 drivers
have opposing effects when comparing the cost-
effectiveness of dabigatran in the 2 age cohorts. Dabiga-
tran is more cost-effective in the 75 cohort than the <75
cohort over shorter time horizons because the baseline risk
of ischemic stroke (and bleeding) is higher in the 75
cohort, magnifying the clinical beneﬁt of dabigatran. This
can be seen in the analyses using a 10-year time horizon in
which the ICER for the 75 cohort is lower (more favorable
for dabigatran) than the ICER for the <75 cohort. In the
lifetime analyses, however, the opposite is true, reﬂecting
the longer remaining life expectancy of the <75 cohort and
their correspondingly greater opportunity to avoid events
and beneﬁt from events avoided. Overall, these 2 effects
counterbalance each other resulting in relatively similar
lifetime ICERs for the <75 and 75 cohorts.
The cost-effectiveness ﬁndings of the present study were
broadly in line with ﬁndings from the recent literature on
these drugs in the US setting. Until now, no study had
examined the cost-effectiveness of 150 mg twice daily
dabigatran versus warfarin in speciﬁc age cohorts. In the
published comparisons of dabigatran 150 mg twice daily
versus dose-adjusted warfarin over an all-ages cohort in the
US setting, the ICERs were within the $100,000 cost per
QALY willingness to pay threshold (ranged from $12,386/
QALY in Freeman and Turakhia17 and Freeman et al18 to
approximately $86,000/QALY in Shah and Gage19). The
ICERs found in our study ($58,962 to $73,694/QALY) fell
well within that range, which provides evidence that our
model was neither overly optimistic nor conservative
regarding cost and effectiveness outcomes of 150 mg twice
daily dabigatran versus warfarin.
This study has a number of strengths. The baseline
CHADS2 distributions of single-year age cohorts were
modeled explicitly based on new analyses of the RE-LY
trial data. This ensured that the efﬁcacy and safety data
comparing dabigatran with warfarin were based on a direct
head-to-head comparison. The model also incorporated
safety-on-treatment data for clinical efﬁcacy and treatment
discontinuation and was able to closely reproduce the intent-
to-treat estimates from RE-LY, avoiding confounding theclinical inputs because of the rates of use and efﬁcacy of
subsequent treatment. The present analysis focused on the
Medicare cost perspective, which is an important payer for
the AF population in the United States. However, because
Medicare does not pay for long-term costs associated with a
nursing home facility, this analysis does not capture the full
cost impact associated with the long-term disability that is
common with stroke and ICH. Sensitivity analysis showed
that the variation around long-term follow-up cost mini-
mally affects the results.
The model adapted for this study has undergone exten-
sive review and validation. The model was peer-reviewed
through publications, including the application of the
model to compare dabigatran with warfarin in Canada and
the United Kingdom6,7 and underwent a comprehensive
review through the assessment process of a number of health
authorities, including but not limited to health technology
assessment bodies in the United Kingdom, Canada, and
Australia. As described in the validation analysis, the model
simulation over a 2-year time horizon was able to closely
reproduce the clinical event rates for dabigatran and
warfarin for the intent-to-treat populations in RE-LY,
providing evidence that the model was well calibrated.
As with all models that are based on clinical trial data,
assumptions must be made to extend the trial ﬁndings to
longer (lifetime) time horizons. In this model, we applied
the age-related relative risks of events found at the
completion of the trial to subsequent years beyond the trial
period. In comparison with some previous models, this
adjustment of the baseline risks over time as the population
ages would lead to more precise projection. It was also
assumed that the international normalized ratio control for
warfarin was the same across all age cohorts. The analysis
incorporated Medicare costs and, therefore, did not reﬂect
the full costs of long-term care, which are limited under the
Medicare program. Thus, severe disability resulting from
events had lower costs in the model than would exist in real-
world practice, which yields a conservative estimate of
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